

## Special Issue

# Development of Vaccines Based on Virus-Like Particles: The 3rd Edition

### Message from the Guest Editors

Basic studies on virus structure and assembly have led to the experimental observation that many viral structural proteins have the intrinsic ability to self-assemble into virus-like particles (VLPs). These VLPs have led to better immunological mimics of whole-virus particles compared to soluble capsid subunits, resulting in the improved effectiveness of vaccines and leading to a renaissance in vaccine development. VLP-based vaccines combine many of the advantages of whole-virus-based and recombinant subunit vaccines, exhibiting a high safety profile. VLPs produced using recombinant protein expression systems can stimulate strong B- and T-cell immune responses and have been shown to exhibit self-adjuvanting abilities. In addition, VLPs can be used as platforms for the multimeric display of foreign antigens of interest derived from viruses or other pathogens (chimeric VLPs). This Special Issue aims to collect recent research work on the design, generation and use of VLPs and chimeric VLPs for the development of both human and veterinary new generation vaccines.

---

### Guest Editors

Dr. Esther Blanco

Center for Animal Health Research (CISA-INIA), Valdeolmos, 28130 Madrid, Spain

Dr. Juan Bárcena

Center for Animal Health Research (CISA-INIA), Valdeolmos, 28130 Madrid, Spain

---

### Deadline for manuscript submissions

closed (30 June 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/191628](https://mdpi.com/si/191628)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).